We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat... Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. Show more
REGULATED INFORMATION Nyxoah Reports First Quarter 2024 Financial and Operating ResultsAnnounced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of...
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or...
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to...
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or...
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), March 29, 2024, 9:30 pm CET / 4:30 pm ET – In accordance with article 15 of the...
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationFirst medical device company to become a corporate...
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002)Reports an Oxygen...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.8825 | 22.8736330498 | 8.23 | 12.21 | 8.23 | 37951 | 9.89139127 | CS |
| 4 | -0.3975 | -3.78211227402 | 10.51 | 12.21 | 8.18 | 28265 | 9.78908169 | CS |
| 12 | -5.4075 | -34.8421391753 | 15.52 | 20 | 8.18 | 44071 | 13.30595125 | CS |
| 26 | 5.0425 | 99.4575936884 | 5.07 | 20 | 4 | 43619 | 10.72830722 | CS |
| 52 | 2.5725 | 34.1180371353 | 7.54 | 20 | 4 | 24442 | 10.28033273 | CS |
| 156 | -19.9075 | -66.3141239174 | 30.02 | 37 | 4 | 17533 | 11.77974188 | CS |
| 260 | -19.9075 | -66.3141239174 | 30.02 | 37 | 4 | 17533 | 11.77974188 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
